Diversion And Misuse Of Stimulant Medication For ADHD Among Illicit Psychostimulant Users
Funder
National Health and Medical Research Council
Funding Amount
$152,534.00
Summary
The practices of diversion and misuse of pharmaceutical stimulants give serious cause for concern due to their potential to increase the risk of drug toxicity, dependence, and serious adverse health consequences. These practices may be particularly harmful among illicit psychostimulant users. This will be the first to study the nature of diversion and misuse of pharmaceutical stimulants among illicit psychostimulant users and the first to examine the associated correlates and consequences.
Droperidol And Olanzapine As Adjuncts To Midazolam For The Acutely Agitated Patient: A Randomised Clinical Trial
Funder
National Health and Medical Research Council
Funding Amount
$187,872.00
Summary
Management of the acutely agitated patient, whether due to severe psychiatric illness or drug intoxication, results in a disproportionate use of Emergency Department resources. Drug sedation is frequently employed when an individual is at risk of harming themselves or others. This study will determine if antipsychotic drugs (droperidol and olanzapine), when added to midazolam (a commonly used sedative), is safer and more efficacious than sedation with midazolam alone.
How Commonly Used Psychoactive Drugs Affect The Hypothalamo-pituitary-adrenal Axis
Funder
National Health and Medical Research Council
Funding Amount
$411,448.00
Summary
The body makes a number of responses when it is subjected to stress, and these include the secretion of hormones from the adrenal gland, including cortisol. It is not surprising that cortisol has effects upon the way the brain operates, nor is it surprising that diseases that are associated with stress (e.g. depression, alcoholism and other psychiatric complaints) create abnormal cortisol secretion. The drugs that are known to be successful in treating conditions such as depression and anxiety h ....The body makes a number of responses when it is subjected to stress, and these include the secretion of hormones from the adrenal gland, including cortisol. It is not surprising that cortisol has effects upon the way the brain operates, nor is it surprising that diseases that are associated with stress (e.g. depression, alcoholism and other psychiatric complaints) create abnormal cortisol secretion. The drugs that are known to be successful in treating conditions such as depression and anxiety have been shown to affect the secretion of cortisol, but, somewhat paradoxically, we do not precisely know how they operate. The aim of this research is to examine how drugs that are commonly used for the treatment of a number of psychiatric conditions (e.g. Prozac, Tofranil, Xanax, morphine and naltrexone) affect the secretion of hormones from the brain that ulitmately regulate the secretion of cortisol. We propose that the effects of these drugs is related to how they operate, and for how long they have been given. The findings generated by this research may help us determine new ways of diagnosing and treating a range of conditions.Read moreRead less
Development Of An In Vivo Pharmacokinetic-pharmacodynamic Model For Evaluation Of Antimalarial Drug Therapy Combinations
Funder
National Health and Medical Research Council
Funding Amount
$120,604.00
Summary
The World Health Organization currently estimates that there are 300-500 million cases of malaria annually, with 1.5-2.7 million deaths. These are staggering data, given that almost 20 antimalarial drugs are now in regular clinical use. Multi-drug resistance is present in most tropical countries where malaria is endemic and there has been a rapid escalation in cases of malaria in developed countries over recent decades (imported by travellers). Clearly, there is a need to ensure that current and ....The World Health Organization currently estimates that there are 300-500 million cases of malaria annually, with 1.5-2.7 million deaths. These are staggering data, given that almost 20 antimalarial drugs are now in regular clinical use. Multi-drug resistance is present in most tropical countries where malaria is endemic and there has been a rapid escalation in cases of malaria in developed countries over recent decades (imported by travellers). Clearly, there is a need to ensure that current and new treatment and prevention strategies are rational and effective. This project is based on the premise that improvements can be made in the in vitro testing process of antimalarial drugs. The experiments will be conducted using mice and a form of malaria that is specific to mice but closely resembles human malaria. In the first stage, the relationship between the amount of a new antimalarial drug (dihydroartemisinin) in the body and the effectiveness of the dose will be tested. These experiments will be repeated using conventional antimalarial drugs such as mefloquine. Information from these studies will subsequently be used to evaluate combinations of antimalarials. The results will be used as the basis of extensive, collaborative clinical studies in South-East Asia that are beyond the scope of this project. The methods used for this research will be important for future testing of new antimalarial drugs or combinations of drugs for the treatment and prophylaxis of malaria.Read moreRead less
NADPH Oxidase In Pathological Angiogenesis In Solid Tumours And Retina
Funder
National Health and Medical Research Council
Funding Amount
$581,989.00
Summary
Understanding blood vessel growth has profound clinical implications for many diseases. Blocking vessel growth is a promising strategy for treatment of cancer and eye complications accompanying diabetes, whereas treatments to stimulate new vessel growth will treat ischemic disorders ie. heart attack and stroke. Here we investigate whether targeting an enzyme that grows blood vessels has potential for making drugs to stop tumor growth or eye damage that occurs with diabetes and premature births.
Role Of Transformation And IAPs In Sensitivity Of Cells To TNFalpha
Funder
National Health and Medical Research Council
Funding Amount
$505,786.00
Summary
Current cancer treatments are ineffective and unpleasant for patients. This is because existing cancer treatments target normal as well as cancer cells. New anti-cancer drugs have been designed to encourage cancer cells to kill themselves, by a process called apoptosis, but may still target normal cells. This project aims to discover why cancer cells are susceptible to a novel anti-cancer drug and a natural ligand called TNF but normal cells are not. This will lead to better treatments.
Apo2L/TRAIL Killing Of Tumour Cells And The Role Of Inhibitor Of Apoptosis Proteins
Funder
National Health and Medical Research Council
Funding Amount
$390,321.00
Summary
Melanomas and Gliomas are tumour types that respond poorly to current treatments. Current treatments are not only sometimes ineffective, but also unpleasant and may cause co-lateral damage. We will test 2 new targetted anti-cancer treatments, that so far appear to have minor side effects in small animal models, on these difficult to treat tumour types to see if and how they kill them. We also want to know whether these independent treatments can work together to kill tumours more effectively. Al ....Melanomas and Gliomas are tumour types that respond poorly to current treatments. Current treatments are not only sometimes ineffective, but also unpleasant and may cause co-lateral damage. We will test 2 new targetted anti-cancer treatments, that so far appear to have minor side effects in small animal models, on these difficult to treat tumour types to see if and how they kill them. We also want to know whether these independent treatments can work together to kill tumours more effectively. Although we will not personally test these drugs in clinical settings, these drugs or similar are currently in preclinical and clinical trials. This means that understanding how these drugs function is of paramount importance and may result in better clinical trials and possibly more rapid acceptance of the use of these drugs in patients.Read moreRead less
There is an ongoing need for the development of new anticancer drugs, particularly those directed against solid tumours. In the past plants have been an extremely valuable source of anticancer agents, including the world s best selling anticancer drug, Taxol, isolated from the Pacific Yew tree. However, such molecules are typically complex and often very expensive to manufacture or extract from natural sources. So far very little attention has been paid to protein-based molecules from plants as ....There is an ongoing need for the development of new anticancer drugs, particularly those directed against solid tumours. In the past plants have been an extremely valuable source of anticancer agents, including the world s best selling anticancer drug, Taxol, isolated from the Pacific Yew tree. However, such molecules are typically complex and often very expensive to manufacture or extract from natural sources. So far very little attention has been paid to protein-based molecules from plants as potential anticancer agents because pharmaceutical companies have focused on organic molecules. In principle protein-based molecules could be produced much more cheaply and thus made available more widely to patients than existing drugs. All that is required are the lead molecules, or proteins that display sufficient anticancer activity to be used as the basis for further optimization. We have discovered a family of plant proteins called the cyclotides that have recently been shown to have considerable promise as anticancer agents. In the current project we will use synthetic chemistry to modify selected amino acids on the surface of this new family of proteins to determine which parts of the molecules are responsible for their activity. We will use this information to design improved analogues. The project is a collaboration between researchers at the Institute for Molecular Bioscience, University of Queensland, who have expertise in the required peptide chemistry and researchers and clinicians at Uppsala University, Sweden who have a range of assays and clinical expertise to test the new molecules. Both groups have been centrally involved in the discovery of the cyclotide family of plant proteins and are committed to developing them as exciting new anticancer agents.Read moreRead less